University Hospital Tuebingen: COVID-19 trials

The registry lists 14 COVID-19 studies with University Hospital Tuebingen as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 3Phase 3 2No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS ApproachRecruitingNCT04873128Not applicable
• A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy AdultsActive, not recruitingNCT05389319Phase 1
• SSC-COVID in Patients After COVID-19CompletedNCT05233553
• Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine LearningStatus unknownNCT04828915
• Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in AdultsCompletedNCT04546841Phase 1
• Frequency of Perforated Appendicitis in Times of COVID-19CompletedNCT04472052
• Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health CentreStatus unknownNCT04446338
• Endoscopic Interventions in Patients With COVID-19CompletedNCT04423003
• Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)Status unknownNCT04377334Phase 2
• NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease ProgressionCompletedNCT04364828Not applicable
• Test and Treat COVID 65plus+WithdrawnNCT04351516Phase 2/3
• Hydroxychloroquine for COVID-19TerminatedNCT04342221Phase 3
• Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)WithdrawnNCT04341285Not applicable
• Hydroxychloroquine for the Treatment of Mild COVID-19 DiseaseTerminatedNCT04340544Phase 2